期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HER-2在新辅助化疗乳腺癌中的表达及其意义分析

Expression of HER-2 in Breast Cancer with Neoadjuvant Chemotherapy and Clinical Signiflcance
暂未订购
导出
摘要 目的检测并分析HER-2在新辅助化疗乳腺癌组织中的表达,探讨新辅助化疗患者中HER-2的临床意义。方法采用免疫组织化学法分别检测HER-2在78例新辅助化疗及22例未化疗乳腺癌组织中的表达状况。结果新辅助化疗组HER-2表达低于未化疗组(28．2％比45．4％,P <0．05);腋淋巴结转移组HER-2表达明显高于腋淋巴结阴性组(42．6％比25．6％,P<0．05)。结论 HER-2可能成为在新辅助化疗乳腺癌患者优于淋巴结状况的一个评价肿瘤生物学行为、预测治疗效果、指导综合治疗方案制定、以及判新预后的重要标志。 Objective To study the clinical significance of expression of HER-2 in breast cancer with neoadjuvant chemothetapy. Methods The expression of HER-2 in 78 cases treated with neoadjuvant chemotherapy and 22 cases treated with only operation were examined by immunohistochemistry. Results The HER-2 expression in neoadjuvant chemotherapy groupwas lower than that of only operation group （P〈0. 05）. The HER-2 expression in lymph node metastatic case were higher than that without lymph node metastasis cases （P〈0. 05）. Conclusion HER-2 is a useful tumor marker in patients treated with neoadiuvant chemotherapy and can be used to evaluate tumor biological behavior, predict the sensitivity of treatment.
作者 陈静 冉立 文小平
机构地区 贵阳医学院附属医院肿瘤科
出处 《贵州医药》 CAS 2006年第5期397-398,共2页 Guizhou Medical Journal
关键词 HER-2 乳腺癌 新辅助化疗 免疫组化 HER-2 Breas cancer Neoadjuvant chemotherapy Immunohistochernistry
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Soomro S,Taylor P,Shepard HM,et al.C-erbB-2 expression in different histological types of invasive breast carcinoma[J].J Clin Pathol,1991,44:211.
  • 2胡勇,饶慧蓉.癌基因c-erbB-2在乳腺癌研究中的进展[J].临床与实验病理学杂志,1993,9(4):298-301. 被引量：23
  • 3Michael PD.Clinical Signiiicance of HER-2 / neu overexpres,sion:Part Ⅰ[J].Principles & Practice of Oncology,1999,13:1-9.
  • 4Slamon DJ,Clark GM,Wong SG,et al.Human breast call-cer:correlation of relapse and survival with amplification of the HER-2/neu oncogene[J].Science,1987,235:177-182.
  • 5Gregory RK,Powles TJ,Salter J,et al.Prognostic relavance of C-erbB-2 expressoin following neoadjuvallt chemotherapy in patients in a randomized trial of neoadiux-ant versHS aajuvallt chemoendocrine therapy[J].Breast Cancer Research and Treatmcnt,2000,59:171-175.
  • 6Wright C,Augus B,Nich Olosoll S,et al.Expression of C-erbB-2 oncoprotein:A prognostic indictor in human breast cancer[J].J Cancer Res,1989,49(8):2 087-2 090.
  • 7张斌,李艳萍,马特,邹俊芝,董卫,张强,赵林.若干生物学指标对淋巴结阴性乳腺癌预后意义的评价[J].中华肿瘤杂志,2000,22(4):298-300. 被引量：15
  • 8Yu D,ring T,Liu B,et al.Overe_xpres.vion of ErbB2 blocks taxol-induced apoptosis by upregulation of p2 lcipl,which inhibits p34cdc2 klnase[J].Mol Cell,1998,2:581-591.
  • 9Mired DC,Clark GM,Tandon AK.et al.HER-2 / neu in lymph node negative breast C～Icel":Prog,aosdc significance of overexpression influenced by the presence of in sire c-cinoma[J].J Clin Oncol,1992,10:599-605.
  • 10Carlomango C,Perrqnc F,Gallo C,et al.C-erbB-2 overex-pression decreases the benefit of adiuvant tamoxifen in early-stage breast cancer without axillary lymph node metastasis[J].J.Ch OncoL,1996,14:2 702-2 708.

二级参考文献2

  • 1A. E. M. A. O’Donoghue,D. N. Poller,J. A. Bell,M. H. Galea,C. W. Elston,R. W. Blamey,I. O. Ellis. Cathepsin D in primary breast carcinoma: Adverse prognosis is associated with expression of cathepsin D in stromal cells[J] 1995,Breast Cancer Research and Treatment(2):137～145
  • 2Pierantonio Bevilacqua,Mattia Barbareschi,Paolo Verderio,Patrizia Boracchi,Orazio Caffo,Paolo Dalla Palma,Salvatore Meli,Noel Weidner,Giampietro Gasparini. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma — results of a multiparametric study[J] 1995,Breast Cancer Research and Treatment(2):205～217

共引文献36

贵州医药
2006年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部